Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aytu Biopharma (AYTU) Gross Margin (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Gross Margin for 12 consecutive years, with 63.46% as the latest value for Q4 2025.

  • Quarterly Gross Margin fell 303.0% to 63.46% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 66.84% through Dec 2025, down 510.0% year-over-year, with the annual reading at 69.04% for FY2025, 621.0% down from the prior year.
  • Gross Margin for Q4 2025 was 63.46% at Aytu Biopharma, down from 66.14% in the prior quarter.
  • The five-year high for Gross Margin was 77.89% in Q4 2023, with the low at 48.12% in Q2 2021.
  • Average Gross Margin over 5 years is 64.13%, with a median of 65.81% recorded in 2022.
  • The sharpest move saw Gross Margin crashed -1621bps in 2021, then skyrocketed 1782bps in 2024.
  • Over 5 years, Gross Margin stood at 53.18% in 2021, then rose by 24bps to 65.81% in 2022, then increased by 18bps to 77.89% in 2023, then fell by -15bps to 66.49% in 2024, then fell by -5bps to 63.46% in 2025.
  • According to Business Quant data, Gross Margin over the past three periods came in at 63.46%, 66.14%, and 67.75% for Q4 2025, Q3 2025, and Q2 2025 respectively.